AndzonBio® is an innovative start-up studio dedicated to accelerating the most promising scientific breakthroughs in the life sciences. Launched in collaboration with AdBio Partners and Inserm Transfert, the AndzonBio® model transforms cutting-edge academic research into biotech start-ups, with the aim of addressing critical unmet medical needs, with each studio dedicated to a particular therapeutic area.
AdBio partners is a venture capital company regulated by the AMF (the French financial markets authority) that invests in a range of life science sectors – particularly in projects with a therapeutic focus. Founded in 2016, AdBio Partners has made 25 European investments in France, Belgium and Spain with two seed funds.
Inserm Transfert, a private subsidiary of the Institut national de la santé et de la recherche médicale (Inserm), is responsible for commercializing the innovations of Inserm and its academic partners in the field of human health, and promotes long-term technology transfers in line with international best practice. Inserm Transfert SA was created in 2000. It manages, within the framework of a Public Service Delegation, the promotion and transfer of knowledge from Inserm’s research laboratories to the industrial world, from the disclosure of inventions to industrial partnerships and the creation of start-ups.
Legal advice :
AndzonBio1 was advised on legal matters by UGGC Avocats with a team comprising partner Charles-Emmanuel Prieur and associate Yaël Messika.
